论文部分内容阅读
目的:探讨西妥昔单抗联合不同化疗一线治疗K-Ras野生型转移性结直肠癌(m CRC)的效果及安全性。方法:选取58例K-Ras野生型m CRC患者,随机分为观察组和对照组,每组29例。对照组采用单纯化疗治疗,观察组采用西妥昔单抗联合化疗治疗,两组均完成8周期治疗。比较两组客观缓解率(ORR)、疾病控制率(DCR),观察两组中位无进展生存期(PFS)、中位总生存期(OS),比较两组皮疹发生率。结果:两组ORR差异无统计学意义(P>0.05),观察组DCR显著高于对照组(P<0.05),观察组中位PFS和中位OS显著长于对照组(P<0.05),观察组皮疹发生率显著高于对照组(P<0.05)。结论:西妥昔单抗联合化疗一线治疗K-Ras野生型m CRC较单纯化疗方案能够显著提高近期疗效,延长患者中位PFS和OS,不良反应以皮疹为主。
Objective: To investigate the efficacy and safety of cetuximab combined with first-line chemotherapy in the treatment of K-Ras wild-type metastatic colorectal cancer (mCRC). Methods: Fifty-eight K-Ras wild type m CRC patients were randomly divided into observation group and control group, with 29 cases in each group. The control group was treated with chemotherapy alone, and the observation group was treated with cetuximab in combination with chemotherapy. Both groups completed 8 cycles of treatment. The objective response rate (ORR) and disease control rate (DCR) were compared between the two groups. The median progression-free survival (PFS) and median overall survival (OS) were compared between the two groups. Results: The ORR of the two groups had no significant difference (P> 0.05). The DCR in the observation group was significantly higher than that in the control group (P <0.05). The median PFS and median OS in the observation group were significantly longer than those in the control group (P <0.05) Group rash incidence was significantly higher than the control group (P <0.05). CONCLUSION: The first-line treatment of K-Ras wild-type mCR with cetuximab combined with chemotherapy can significantly improve the short-term curative effect, prolong the median PFS and OS, and the side effects are mainly rash.